Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
How do you manage upper esophageal squamous cell in situ disease that is not amenable to endoscopic mucosal resection?
Related Questions
For patients with locally advanced rectal cancer who desire organ preservation and can tolerate fluoropyrimidine but not oxaliplatin, what is the appropriate treatment approach?
In what situations would you treat a rectal mass as cancer despite negative biopsies?
Would you offer post-operative radiation for a T2N0 rectal cancer with less than 12 lymph nodes found in the specimen after LAR?
How often do you see pseudoprogession in pancreatic cancer after SBRT, and how do you manage it if the patient is planed for surgical exploration?
Would you offer neoadjuvant radiation therapy with concurrent chemotherapy for a T4 rectal carcinoma with an associated rectovesical fistula?
How would you sequence treatment of a synchronous IC1 high-grade serous ovarian cancer and cT3N1 rectal cancer?
How do you approach SBRT and constraining healthy liver for a small liver?
How would you treat synchronous high-risk prostate and rectal adenocarcinomas in an elderly man where the rectal cancer was resected secondary to obstruction (T3N0)?
When using SBRT to treat unresectable pancreatic cancer after induction chemotherapy, do you treat elective lymph nodes?
For insurance, how do you justify medical necessity for IMRT to the pancreas in the preoperative, unresectable, and post-operative settings?
